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All-cause mortalityAims: There are safety concerns related to sulphonylurea treatment. The objective of this
nationwide study was to compare the risk of cardiovascular disease (CVD), all-cause mor-
tality and severe hypoglycemia in patients with type 2 diabetes (T2D) starting second-line
treatment with either metformin + sulphonylurea or metformin + dipeptidyl peptidase-4
inhibitor (DPP-4i).
Methods: All patients with T2D in Sweden who initiated second-line treatment with met-
formin + sulphonylurea or metformin + DPP-4i during 2006–2013 (n = 40,736 and 12,024,
respectively) were identified in this nationwide study. The Swedish Prescribed Drug Regis-
ter and the Cause of Death and National Patient Registers were used, and Cox survival
models adjusted for age, sex, fragility, prior CVD, and CVD-preventing drugs were applied
to estimate risks of events. Propensity score adjustments andmatching methods were used
to test the results.
Results: Of 52,760 patients; 77% started metformin + SU and 23% metformin + DPP-4i.
Crude incidences for severe hypoglycemia, CVD, and all-cause mortality in the SU cohort
were 2.0, 19.6, and 24.6 per 1000 patient-years and in the DPP-4i cohort were 0.8, 7.6, and
14.9 per 1000 patient-years, respectively. Sulphonylurea compared with DPP4i was associ-
ated with higher risk of subsequent severe hypoglycemia, fatal and nonfatal CVD, and
all-cause mortality; adjusted HR (95% CI): 2.07 (1.11–3.86); 1.17 (1.01–1.37); and 1.25 (1.02–
1.54), respectively. Results were confirmed by additional propensity-adjusted and matched
40 d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 1 7 ( 2 0 1 6 ) 3 9 –4 7analyses. Among the SU drugs, glibenclamide had the highest risks.
Conclusions: Metformin + SU treatment was associated with an increased risk of subse-
quent severe hypoglycemia, cardiovascular events, and all-cause mortality compared with
metformin + DPP4i. Results from randomized trials will be important to elucidate causal
relationships.
 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The prevalence of type 2 diabetes treated with glucose-
lowering drugs is increasing, and has now been estimated
at 4.4% in Sweden [1]. It is recommended in the 2015 guideli-
nes from the American Diabetes Association that glucose-
lowering drug (GLD) therapy should be initiated as metformin
monotherapy. When this fails, sulphonylurea or a dipeptidyl
peptidase (DPP)-4 inhibitor is frequently added. Sulphony-
lurea, which has been available for 50 years, is still primarily
used because of its efficacy and low cost, but it has known
side effects such as hypoglycemia and weight gain [2]. DPP-4
inhibitors have demonstrated a lower risk of hypoglycemia
and weight gain than sulphonylurea [3–5], and is therefore
recommended for patients at increased risk of hypoglycemia
and with established obesity [6,7]. In addition, DPP-4 inhibitor
shows a neutral effect on risk of cardiovascular death and
myocardial infarction compared with placebo [3–5,8–10]
although there have been reports of increased numbers of
non-fatal heart failure events [8].
Results from observational studies have raised safety con-
cerns regarding increased risk of cardiovascular disease (CVD)
and all-cause mortality in patients treated with sulphony-
lurea [11–18]. Hypoglycemia shows a strong association with
cardiovascular events, and this could partially explain the
reported increased risk of CVD and mortality with sulphony-
lurea [10,19]. Currently, no randomized trials have directly
compared metformin combinations with sulphonylurea and
DPP-4 inhibitor using CVD and mortality outcomes, but a lar-
ger randomized study is currently ongoing (Cardiovascular
outcome study of linagliptin versus glimepiride in patients
with type 2 diabetes [CAROLINA]), which is expected to be
completed in late 2018 [20,21]. Meanwhile, observational
studies may add to our knowledge of the association between
sulphonylurea use and cardiovascular events in patients with
type 2 diabetes.
The aim of this observational, full-population study was to
investigate the risk of severe hypoglycemia, fatal and nonfatal
CVD (unstable angina, myocardial infarction, or stroke), and
all-cause mortality associated with combination treatment
with either sulphonylurea or DPP-4 inhibitor added to met-
formin, using national healthcare registries in Sweden.
2. Material and methods
2.1. Data sources
This observational registry study utilized data from Swedish
national registries: the Prescribed Drug Register covering alldrug prescriptions filled since 2005 using Anatomical Thera-
peutic Chemical (ATC) codes; the Cause of Death Register
(established 1961); the National Patient Register covering all
hospitalisations and discharge diagnoses since 1987 and all
out-patient hospital visits since 2001. All three registers are
held by the Swedish National Board of Health and Welfare
(NBHW).
2.2. Study population
All patients with a filled prescription for an incident combina-
tion treatment of either a sulphonylurea or a DPP-4 inhibitor
together with metformin during the time period July 1 2006 to
end of 2013 were identified. Patients had to be receiving
monotherapy with one non-insulin antidiabetic drug (NIAD)
prior to the start of combination treatment, and the index
date was defined as the date of combination treatment initia-
tion (sulphonylurea or metformin or DPP-4 inhibitor). Second-
line treatment was defined as concomitant use of two or more
NIADs, or as initiation of insulin treatment. Switching from
NIAD to another was not considered as second-line treat-
ment, unless a new prescription of the first-line drug was
filled within 1 year after the switch, in which case the starting
date of the second antidiabetic drug was the index date.
Patients with a diagnosis of gestational diabetes (Interna-
tional Classification of Diseases [ICD] code 10: O24.4) within
1 year of the index date and patients with type 1 diabetes
were excluded. (See Online-Only Supplementary Table 1 for
ICD diagnoses and ATC codes.) Patients with type 1 diabetes
were arbitrarily defined as those with a registered type 1 dia-
betes diagnosis (ICD-10 E10) and treated with insulin during
their first year of GLD treatment, or aged under 30 years at
the start of insulin medication, or aged under 15 years at
the start of any diabetes medication. The main analyses were
done according to an on-treatment approach, and patients
were observed from the index date until: a gap of at least
6 months in filled prescription of metformin and sulphony-
lurea or DPP-4 inhibitor; death; or December 31, 2013. In addi-
tion, ITT (intention-to-treat) analyses were performed as
above, but also including those with interrupted or changed
treatment. The study cohort was formed among patients with
type 2 diabetes moving from treatment with one NIAD to dual
NIAD, as outlined in Fig. 1.
Individual patient-level data from the national registers
were linked using personal identification numbers, which
are assigned at birth and whose use is mandatory in dealing
with the public healthcare system. Data linkage was per-
formed by the NBHW and the linked database was managed
at Statisticon AB, Stockholm, Sweden. The study protocol
GLD-treated T2DM patients
N = 417,691 Patients treated with:
• 2 NIADs, n = 37,681
• 3 NIADs, n = 4282  
• Insulin, n = 78,170
Patients remaining on 1 NIAD alone 
throughout the study period, n = 195,473
Patients treated with:
• 3 NIADs, n = 105
• Insulin, n = 33,633
1 NIAD as first-line treatment
n = 297,558
Second-line treatment 
n = 102,085
Metformin + SU
n = 40,736
Metformin + DPP-4i
n = 12,024
Other combinations
n = 15,587
2 NIADs
n = 68,347
Fig. 1 – Flowchart on establishment of patient population.
All patients with type 2 diabetes in Sweden who were on
GLD treatment at the start of the study period (2006-07-01),
as well as incident cases who initiated treatment thereafter,
were surveyed for treatment changes until the end of the
study period (2013-12-31). The resulting study cohort, i.e.
patients initiating second-line treatment with metformin in
combination with either a DPP-4 inhibitor or a
sulphonylurea, is indicated in bold. DPP, dipeptidyl
peptidase; GLD, glucose-lowering drug; NIAD, non-insulin
antidiabetic drug.
d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 1 7 ( 2 0 1 6 ) 3 9 –4 7 41was approved by the Stockholm regional ethics committee
(registration number 2013/2206-31). Baseline treatments,
defined by ATC codes, were defined as any identified filled
prescription of the treatment of interest during the year prior
to the index date.
Three endpoints were defined as follows: (1) Severe hypo-
glycemia a main or secondary diagnosis in the inpatient reg-
ister of hypoglycemia (E16.0, E16.1, or E16.2) or diabetes with
coma (ICD-10 E10.0, E11.0, E12.0, E13.0, or E14.0), as these
codes are typically used for hypoglycemia requiring third
party assistance. (2) Fatal and nonfatal CVD – a main diagno-
sis in the inpatient register of myocardial infarction (I21),
ischemic stroke (I63–I64), unstable angina pectoris (I20.0), or
cardiovascular death (death with an ICD-10 code I diagnosis
as primary cause of death). (3) Death of any cause.
2.3. Statistical analyses
The time from initiation of second-line treatment to a clinical
event (severe hypoglycemia, fatal or nonfatal CVD, or all-
cause mortality) was visualized using Kaplan–Meier graphs.
Patients were censored at treatment discontinuation, death,
or study period end.
Statistical analyses comparing treatments (metformin
+ DPP-4 inhibitor vs. metformin + sulphonylurea) was per-
formed using Cox proportional hazards models. Two separate
adjustment models were determined for risk of severe hypo-
glycemia and for fatal and nonfatal CVD and all-cause mor-
tality. Directed acyclic graphs [22] were used to minimize
the risk of bias and identify the two primary adjustment mod-
els (Online-Only Supplementary Figs. 1 and 2).The model for estimating the risk of severe hypoglycemia
was adjusted for age and fragility (defined as at least 3 days of
hospitalization during the year prior to the index date). The
model for fatal and nonfatal CVD was adjusted for age, sex,
fragility, prior CVD, and use of statins, low-dose aspirin, and
antihypertensives. Prior history of CVD was assessed in the
National Patient Register from 1987 until index date.
The main analysis was performed using an on-treatment
approach, in which a treatment chain was regarded as unin-
terrupted if a medication of interest had a prescription filled
within 6 months of the prior time of a filled prescription. As
a sensitivity analysis, an intention-to-treat (ITT) approach
was adopted, in which patients were analyzed according to
their index medication combination (with at least two dis-
penses) irrespective of subsequent switches or treatment
interruption or discontinuation.
A separate analysis, irrespective of treatment combina-
tion, was performed to compare two patient groups, those
with or without any event of severe hypoglycemia, and exam-
ine the association with fatal and nonfatal CVD using a Cox
proportional hazard model adjusted for age, sex, fragility,
and prior CVD. This analysis is based on the same cohort used
in the main analysis, and follow-up started at the date of ini-
tiation of metformin + sulphonylurea or metformin + DPP-4
inhibitor. The proportional hazard assumptions were
assessed by examining Schoenfeld residuals.
Since this is a clinical effectiveness study to assess two dif-
ferent treatment strategies a propensity score adjusted and a
propensity score match model were additional used to test
the results from the adjusted Cox proportional hazard model.
Propensity scores were calculated using age, sex, fragility,
prior CVD, and use of statins, low-dose aspirin, and antihy-
pertensives. They were used in propensity score adjusted sur-
vival models and in propensity score matching of SU and
DPP-4 inhibitor treatment groups (2:1 using a caliper of 0.2
when identifying matches). The matching was performed
using the Match function in the R package Matching [23].
A P value below 0.05 was considered significant, but
because no adjustment for multiplicity was performed, P val-
ues should be interpreted with caution. All analyses were
conducted using R statistical software (R version 3.2.3) [24].
3. Results
3.1. Patient characteristics and treatments
A total of 52,760 patients with type 2 diabetes initiated
second-line treatment with metformin + sulphonylurea or
metformin + DPP-4 inhibitor during 2006–2013. Of these,
77.2% initiated metformin + sulphonylurea and 22.8% met-
formin + DPP-4 inhibitor. These regimens were the two most
commonly seen second-line dual NIAD treatments, followed
by a number of less frequently seen dual NIAD combinations
(Fig. 1).
The patients in themetformin + sulphonylurea group were
slightly older than those in the metformin + DPP-4 inhibitor
group, were less frequently men, had slightly more frequent
history of cardiovascular- and microvascular disease (Table 1).
Antihypertensive and low-dose aspirin treatments differed
T ble 1 – Baseline characteristics of patients initiated on either sulphonylurea (SU) or DPP-4 inhibitor (DPP-4i) in combination with metformin.
All patients Matched patients (2:1)
Metformin + SU Metformin + DPP-4i Total Metformin + SU Metformin + DPP-4i Total
umber of patients, N 40,736 12,024 52,760 23,846 11,923 35,769
ge, years, mean (SD) 65.3 (11.9) 61.1 (10.9) 64.4 (11.8) 61.3 (11.1) 61.3 (10.8) 61.3 (11.0)
ex, male, n (%) 24,044 (59.0) 7510 (62.5) 31,554 (59.8) 14,907 (62.5) 7431 (62.3) 22,338 (62.5)
omorbidities, n (%)
VD 13,143 (32.3) 3340 (27.8) 16,483 (31.2) 6698 (28.1) 3322 (27.9) 10,020 (28.0)
Myocardial infarction 3456 (8.5) 895 (7.4) 4351 (8.2) 1731 (7.3) 890 (7.5) 2621 (7.3)
STEMI 1579 (3.9) 417 (3.5) 1996 (3.8) 788 (3.3) 416 (3.5) 1204 (3.4)
NSTEMI 2368 (5.8) 602 (5.0) 2970 (5.6) 1192 (5.0) 597 (5.0) 1789 (5.0)
Unstable angina 1753 (4.3) 486 (4.0) 2239 (4.2) 929 (3.9) 485 (4.1) 1414 (4.0)
Angina pectoris 7140 (17.5) 1915 (15.9) 9055 (17.2) 3719 (15.6) 1905 (16.0) 5624 (15.7)
Heart failure 2468 (6.1) 560 (4.7) 3028 (5.7) 1132 (4.7) 555 (4.7) 1687 (4.7)
Atrial fibrillation 3369 (8.3) 802 (6.7) 4171 (7.9) 1496 (6.3) 802 (6.7) 2298 (6.4)
Stroke 3225 (7.9) 661 (5.5) 3886 (7.4) 1488 (6.2) 658 (5.5) 2146 (6.0)
Hemorrhagic 2326 (5.7) 457 (3.8) 2783 (5.3) 1008 (4.2) 456 (3.8) 1464 (4.1)
Ischemic 278 (0.7) 65 (0.5) 343 (0.7) 150 (0.6) 64 (0.5) 214 (0.6)
Transitory ischemic attack 716 (1.8) 154 (1.3) 870 (1.6) 357 (1.5) 153 (1.3) 510 (1.4)
Peripheral artery disease 1432 (3.5) 343 (2.9) 1775 (3.4) 701 (2.9) 341 (2.9) 1042 (2.9)
idney disease 430 (1.1) 134 (1.1) 564 (1.1) 240 (1.0) 131 (1.1) 371 (1.0)
icrovascular disease 7429 (18.2) 1743 (14.5) 9172 (17.4) 3953 (16.6) 1731 (14.5) 5684 (15.9)
evere hypoglycemia 374 (0.9) 68 (0.6) 442 (0.8) 196 (0.8) 67 (0.6) 263 (0.7)
ancer 5528 (13.6) 1337 (11.1) 6865 (13.0) 2660 (11.2) 1336 (11.2) 3996 (11.2)
hronic obstructive pulmonary disease 1087 (2.7) 290 (2.4) 1377 (2.6) 541 (2.3) 290 (2.4) 831 (2.3)
reatments, n (%)
VD risk treatment 33,758 (82.9) 10,269 (85.4) 44,027 (83.4) 20,220 (84.8) 10,169 (85.3) 30,389 (85.0)
Antihypertensives 29,064 (71.3) 8833 (73.5) 37,897 (71.8) 17,398 (73.0) 8746 (73.4) 26,144 (73.1)
Statins 21,591 (53.0) 7269 (60.5) 28,860 (54.7) 14,308 (60.0) 7189 (60.3) 21,497 (60.1)
Low-dose aspirin 14,645 (36.0) 4063 (33.8) 18,708 (35.5) 8005 (33.6) 4036 (33.9) 12,041 (33.7)
Beta blockers 15,966 (39.2) 4654 (38.7) 20,620 (39.1) 9178 (38.5) 4618 (38.7) 13,796 (38.6)
ower limb amputations 89 (0.2) 13 (0.1) 102 (0.2) 43 (0.2) 13 (0.1) 56 (0.2)
VD, cardiovascular disease (unstable angina, myocardial infarction, or stroke); DPP, dipeptidyl peptidase; NSTEMI, non-ST-segment-elevation myocardial infarction; SD, standard deviation; STEMI,
T-segment-elevation myocardial infarction.
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Fig. 2 – Kaplan–Meier curves and adjusted HRs for (A) severe
hypoglycemia, (B) fatal and nonfatal CVD, and (C) all-cause
mortality. CVD, cardiovascular disease; DPP-4i, dipeptidyl
peptidase-4 inhibitor; HR, hazard ratio; MET, metformin; SU,
sulphonylurea. These analyses were performed in patients
remaining on the initiated 2nd-line treatment.
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were substantially more often prescribed in the metformin
+ DPP-4 inhibitor group (Table 1).
Patients were followed from initiation of dual NIAD treat-
ment (occurring during the period July 1, 2006 to December
31, 2013) until death or end of the study period (December
31, 2013). Thus, the follow-up time ranged up to 7.5 years.
The median follow-up time for the metformin + sulphony-
lurea and metformin + DPP-4 inhibitor groups was 3.4 and
2.5 years, respectively, and the number of patient-years was
143,344 and 32,133, respectively. The most frequently filled
prescriptions for sulphonylureas were glibenclamide (41.7%),
glipizide (34.9%), and glimepiride (23.4%), while among the
DPP-4 inhibitors, prescriptions for sitagliptin, saxagliptin,
and vildagliptin were filled for 80.3%, 5.4%, and 2.1% of
patients with type 2 diabetes, respectively (Online-Only Sup-
plementary Table 2a). The metformin dose at index was 21%
higher in the metformin + DPP-4 inhibitor group than in the
metformin + sulphonylurea group (Online-Only Supplemen-
tary Table 2a).
3.2. Risk of events in the two treatment groups
The main results were obtained by on-treatment analyses. In
the metformin + sulphonylurea group, the crude numbers
(incidence per 1000 patient-years) of severe hypoglycemia,
fatal and nonfatal CVD, and all-cause death were 120 (2.0),
1153 (19.6), and 1420 (24.6), respectively. The corresponding
results for the metformin + DPP-4 inhibitor group were 11
(0.8), 105 (7.6), and 204 (14.9). As illustrated by the Kaplan–
Meier curves (Fig. 2A–C), the increased incidence in the met-
formin + sulphonylurea group of all types of events can be
observed already in the first 6 months, with a continued
increase in separation between the curves with follow-up
time.
3.3. Adjusted analyses
In analyses adjusting for known risk factors, metformin
+ sulphonylurea compared with metformin + DPP-4 inhibitor
as second-line treatment was associated with a higher risk
of severe hypoglycemia, fatal and nonfatal CVD and all-
cause mortality. Adjusted hazard ratios (95% CI) in on-
treatment analyses were as follows: 2.07 (1.11–3.86), 1.17
(1.01–1.37), and 1.25 (1.02–1.54), respectively (Fig. 2 and
Table 2). The ITT analyses yielded similar results with hazard
ratios (95% CI) of 1.71 (1.19–2.44), 1.11 (1.01–1.21), and 1.25
(1.12–1.38) for severe hypoglycemia, fatal/ nonfatal CVD and
all-cause mortality, respectively. Details are shown in Supple-
mentary Table 3.
3.4. Propensity score adjusted analyses
Propensity score adjustments survival analyses resulted in
slightly greater differences between SU and DPP4 inhibitor
treatment for severe hypoglycemia, CVD and all-causemortality
compared to the adjusted survival analyses, 2.08 (1.11–3.89),
1.21 (1.04–1.40) and 1.35 (1.10–1.65), respectively (Table 2).3.5. Propensity matched analyses
Propensity matching decreased the total number of patients
from 52,760 to 35,769, i.e. 16,991 (32%) patients could not be
matched. The resulting groups were very similar in essen-
tially all baseline parameters (Table 1). Hazard ratios were
1.88 (0.98–3.62), 1.23 (1.05–1.44) and 1.43 (1.55–1.77) for severe
hypoglycemia, CVD and all-cause mortality, respectively
(Table 2). This was very similar to the primary adjusted sur-
vival analysis.
Table 2 – Adjusted hazard ratios (HRs) in patients treatedwithmetformin + sulphonylurea (SU) versus metformin + dipeptidyl
peptidase-4 inhibitors (DPP-4i) using multivariate adjusted Cox proportional hazard analyses, propensity-adjusted analyses
and propensity-matched patients (2:1). Univariate analyses of single variables used in the multivariate adjusted survival
models are also presented.
Severe hypoglycemia Fatal and nonfatal CVD All-cause mortality
HR 95% CI p HR 95% CI p HR 95% CI p
Multivariate adjusted (SU vs DPP-4i) 2.07a 1.11–3.86 0.022 1.17b 1.01–1.37 0.035 1.25b 1.02–1.54 0.030
Propensity-adjusted (SU vs DPP-4i) 2.08a (1.11–3.89) 0.021 1.21b (1.04–1.40) 0.014 1.35b (1.10–1.65) 0.004
Propensity-matched (SU vs DPP-4i) 1.88c (0.98–3.62) 0.057 1.23c (1.05–1.44) 0.010 1.43c (1.15–1.77) 0.001
Age (per year) 1.05 1.03–1.06 <0.001 1.05 1.05–1.06 <0.001 1.11 1.10–1.12 <0.001
Fragile (yes) 2.02 1.30–3.15 0.002 1.94 1.72–2.19 <0.001 2.15 1.89–2.46 <0.001
Female sex – – – 0.76 0.68–0.84 <0.001 0.80 0.71–0.89 <0.001
Prior CVD (yes) – – – 2.52 2.24–2.83 <0.001 1.46 1.27–1.67 <0.001
Statins (yes) – – – 0.74 0.66–0.82 <0.001 0.63 0.56–0.71 <0.001
Antihypertensives (yes) – – – 1.11 0.97–1.27 0.137 0.92 0.80–1.06 0.250
Low-dose aspirin (yes) – – – 1.27 1.13–1.42 <0.001 1.10 0.97–1.24 0.126
CVD, cardiovascular disease; DPP-4i, dipeptidyl peptidase; HR, hazard ratio.
a Adjusted for age and fragility.
b Adjusted for age, sex, fragility, prior CVD, and use of statins, low-dose aspirin, and antihypertensives.
c Matched by age, sex, fragility, prior CVD, and use of statins, low-dose aspirin, and antihypertensives. Other HRs for single variables are
unadjusted.
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In patients with type 2 diabetes, regardless of treatment
group, who had an episode of severe hypoglycemia during
follow-up compared with those who did not, the risk of fatal
and nonfatal CVD was increased 1.5-fold (adjusted hazard
ratio 1.51, 95% CI 1.21–1.88, P < 0.001).
3.7. Risk of events within sulphonylurea class
In comparison with metformin + DPP-4 inhibitor all sulpho-
nylurea agents in combination with metformin had numeri-
cally increased risk of fatal-/nonfatal CVD and all-cause
mortality, i.e. glibenclamide (25% and 37% respectively), glip-
izide (11% and 17%) and glimepiride (11% and 11%), however
only glibenclamide use reached statistical significance
(Online-Only Supplementary Table 2b). Based on the limited
number of events (81, 19 and 20 for the glibenclamide, glip-
izide and glimepiride groups, respectively), risk of severe
hypoglycemia was numerically increased with glibenclamide
and glimepiride, where the former reached statistical signifi-
cance (Online-Only Supplementary Table 2b).
4. Discussion
In this nationwide register-based study metformin + sulpho-
nylurea and metformin + DPP-4 inhibitor were the most com-
mon non-insulin second-line treatment strategies in patients
with type 2 diabetes. Using three different statistical meth-
ods, sulphonylurea compared to DPP-4 inhibitors, in combi-
nation with metformin, was associated with a 88–107%, 17–
23%, and 25–43% increased risk of severe hypoglycemia, fatal
and nonfatal CVD, and all-cause mortality, respectively. This
was seen after adjustment for comorbidities and other risk
factors. Propensity score adjusted and matched analyses
yielded similar results compared with the primary adjusted
survival analyses, and this consistency supports the robust-ness of the findings. The increased risk associated with SU
can be observed early after initiation of second-line treatment
and continues to increase with follow-up time. We also found
a strong association between severe hypoglycemia and CVD,
in support of the above-reported findings. These results sup-
port the association of increased CVD risk with metformin
+ sulphonylurea treatment described in previous reports
[16,25].
In a Danish nationwide study of patients with type 2 dia-
betes without a prior history of CVD, Mogensen et al. found
that metformin + sulphonylurea was associated with
increased risk of cardiovascular and all-cause mortality com-
pared with DPP-4 inhibitor: 1.8-fold and 1.5-fold, respectively
[25]. Their use of a different statistical method, Poisson
regression, allowed patients to switch groups and contribute
risk time on the new treatment, whereas we used an on-
treatment approach with censoring at treatment discontinu-
ation. The consequences of these different statistical
approaches are difficult to assess, but it may be speculated
that the increased on-treatment time in the Danish study
increased the number of registered events, thereby resulting
in a numerically increased risk estimation. Still, the numeric
direction for CVD mortality related to metformin + sulphony-
lurea treatment was similar to our fatal and nonfatal CVD
rate, and estimated risks of all-cause mortality were also sim-
ilar in both studies.
Using data from the Clinical Practice Research Datalink in
the UK [26], Morgan et al. found similar associated risks of
CVD and all-cause mortality with metformin + sulphonylurea
versus metformin + DPP-4 inhibitor: 1.4-fold and 1.7-fold,
when using a similar statistical method (adjusted Cox regres-
sion) (15). To compare statistical methods, they used three dif-
ferent statistical methods: full- (adjusted Cox regression),
direct-, and propensity-matched cohorts. Small numerical
differences were found between the methods, but the two lat-
ter methods seemed to generate higher risk estimates. In
their full population design, they used only laboratory mea-
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whereas we used only history of CVD and cardiovascular pre-
ventive treatment. When comparing metformin in combina-
tion with sulphonylurea versus DPP-4 inhibitor, irrespective
of statistical method, all their results were of the same direc-
tion and magnitude as those in our study. Recently Seong
et al. published results from the Korean National Health
Insurance claims database, also showing that metformin
+ sulphonylurea was associated with a 1.2-fold higher risk
of nonfatal CVD compared with metformin + DPP-4 inhibitor
(17). They used an on-treatment approach and their risk esti-
mates are similar to our results. A nationwide study from the
Taiwan National Health Insurance database by Chang et al.
reported numerically increased 1.1-fold (1.11 [95% CI 0.98–
1.27]) risk of nonfatal CVD with metformin + sulphonylurea
versus metformin + DPP-4 inhibitor (16). This study used an
intention-to-treat approach, and their nonsignificant finding
is identical with our significant intention-to-treat result of
1.11 (95% CI 1.01–1.21). The low number of patients treated
with metformin + DPP-4 inhibitor (n = 2242) might very well
have resulted in too low power for CVD risk estimations.
In this study, we have demonstrated a markedly increased
risk of severe hypoglycemia associated with sulphonylurea,
compared with DPP-4 inhibitors. It is also already well known
that sulphonylurea in comparison with DPP-4 inhibitor treat-
ment is associated with increased risk of hypoglycemia,
which in turn has been reported to be strongly associated
with CVD and mortality [3–5,10,19,27–29]. Hypoglycemic
responses, such as sympathoadrenergic activation, have been
suspected to trigger CVD and might act as a causal pathway
between sulphonylurea treatment and risk of CVD and mor-
tality, and may contribute to serious cardiac arrhythmias
[19]. We also found an association between occurrence of sev-
ere hypoglycemia and CVD events, similar to another study
[19], in support of this suggested causal mechanism. In addi-
tion, the early separation of event curves for CVD and all-
cause death, between the two treatment groups, is compati-
ble with hypoglycemia being a contributing factor. The hypo-
glycemia risk is known to be increased, very early after the
start of sulphonylurea medication [30], as noticed in our
study.
Myocardial ischemic preconditioning has also been dis-
cussed as a potential explanation for the harmful CVD effects
observed with sulphonylurea. Sulphonylurea promotes the
release of insulin from beta cells by binding to the sulphony-
lurea receptor, inhibiting the ATP-sensitive potassium chan-
nels [31]. However, sulphonylurea receptors are also present
in cardiac muscle cells, and inhibition of ATP-sensitive potas-
sium channels impairs ischemic preconditioning [32,33]. Con-
sequently, the mechanism for cardiac muscle cells to survive
brief ischemic events is disturbed, which may translate to
increased CVD risk [34].
Numerically increased risk of fatal-/nonfatal CVD and all-
cause mortality was observed with all sulphonylureas + met-
formin, compared to DPP-4 inhibitors + metformin. In the cur-
rent study, treatment with glibenclamide was associated with
the highest mortality-, and CVD risks compared to the other
sulphonylureas. This finding might be explained by its higher
unselective binding to cardiac muscle cells [34], leading to
impaired cardiac preconditioning [32,33], and also by itshigher risk of hypoglycemia [35] compared to other sulphony-
lureas. The increased all-cause mortality associated with
glibenclamide is supported by a recently published meta-
analysis by Simpson et al. [36], demonstrating variations in
all-cause mortality risks within the sulphonylurea class.
Notably, gliclazide, which never was introduced on the Swed-
ish market, has been reported to have the lowest cardiovascu-
lar risk in mono- or combination therapy compared to other
sulphonylureas [14,37]. In our study, severe hypoglycemia risk
was increased with glibenclamide and glimepiride compared
to DPP-4 inhibitors in combination with metformin. Glipizide,
on the other hand, did not display any significant increase of
risk, albeit this has been reported in randomized controlled
trials [4,5]. Taken together, current and previous results sug-
gest that short-acting glipizide might carry less risk of severe
hypoglycemia when compared to long-acting sulphonylureas.
Importantly, interpretation of severe hypoglycemia risk for
the different sulphonylureas should be made with caution
because of the very limited number of events in our study.
Another partial explanation for the increased CVD risk
shown with sulphonylurea could be that treatment with
DPP-4 inhibitor is not associated with any weight gain, in con-
trast to the association of sulphonylurea treatment withmod-
erate weight gain. Moderate weight gain has been strongly
associated with increased risk of cardiovascular death and
all-cause mortality [38,39]. Furthermore, in subgroup analyses
of the Trial to Evaluate Cardiovascular Outcomes after Treat-
ment with Sitagliptin (TECOS), a positive CVD-preventive
effect of DPP-4 inhibitor was reported in obese patients, sug-
gesting that body mass index might be an important clinical
measurement when considering blood glucose-lowering drug
treatment [9]. This reasoning is obviously speculative, and
further studies are needed to explore such associations.
A strength of the present work is the population-based,
nationwide and unselected real-world study design, which
provides a high external validity. In addition, this is a study
with full (100%) register coverage for hospitalizations, filled
drug prescriptions, and cause of death in a country with an
established and complete public healthcare system. Diag-
noses in the Swedish Patient Registry have been reported to
have high validity [40], and few patients are lost to follow-
up. Moreover, the directed acyclic graphs used to create the
optimal adjustments of hazard models should provide mini-
mal bias [22].
Observational studies such as this obviously have limita-
tions. The present study has no information on laboratory
measurements, lifestyle parameters, primary healthcare
data, or socioeconomic data, and consequently there may
be remaining confounding factors. Moreover, glucose-
lowering drugs such as metformin could potentially have
been used for reasons other than type 2 diabetes treatment
(such as polycystic ovarian syndrome or prediabetes), which
could influence the results. However, such usage should be
very small compared with the type 2 diabetes indication.
Specifically, the combination treatments addressed in this
study (i.e. metformin together with either a DPP4 inhibitor
or a sulphonylurea) would have been used to a negligible
extent for conditions other than type 2 diabetes. In the
propensity score -matched analyses, the numerical risk of
severe hypoglycemia reflected the unmatched analyses, but
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likely due to lack of power, with low number of events and a
substantially reduced study cohort (by 32%). We have no
information on emigration, which could result in loss to
follow-up. However, the on-treatment analyses used in this
study should minimize the effects of patients moving out of
Sweden. Furthermore, our assessment of severe hypo-
glycemia is crude, including only events leading to hospital
admission. It was not possible to evaluate other hypoglycemic
events in this register-based study. Another limitation is that
patients with a recorded hypoglycemia had to survive until
this occasion and, if anything, this would underestimate the
total mortality rate in these patients compared to those with-
out a hypoglycemic event.
Although a major concern with the present analyses is the
non-randomized approach with risk for confounding by indi-
cation, the data are an in agreement with several other obser-
vational studies reporting data raising concerns about the use
of sulphonylureas compared with DPP-4 inhibitor, both as
monotherapy and in combinations with metformin
[13,14,16,18,25]. Of these studies, four papers from Denmark,
South Korea, Sweden, and the UK have compared metformin
combinations with sulphonylurea versus DPP-4 inhibitor
using different analytic approaches and data sources. In spite
of this, the resulting risk estimates are similar and show
increased clinical risks for metformin + sulphonylurea com-
pared with metformin + DPP-4 inhibitor [16,25]. These concor-
dant study results may thus demonstrate the robustness of
epidemiological methods using large register datasets to
assess specific research questions. Despite unknown factors
potentially confounding the results, the results may raise
concerns regarding the cardiovascular safety of sulphony-
lurea while awaiting results from the CAROLINA study [21].
5. Conclusion
This nationwide register-based study shows that type 2 dia-
betes patients that received a combination of metformin
and sulphonylurea as second-line treatment had an increased
risk of subsequent severe hypoglycemia, cardiovascular
events and all-cause mortality compared with those receiving
metformin in combination with a DPP-4 inhibitor. The causal
relationships remain to be further elucidated, but results
from this and other observational studies should be consid-
ered in the choice of treatment for patients with type 2 dia-
betes, until results from future randomized trials are
available.
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